

Electronic Supplementary Information

Enantioselective Synthesis of 2-Substituted and 3-Substituted Piperidines through a Bromoaminocyclization Process

Ling Zhou,^a Daniel Weiliang Tay,^{a,b} Jie Chen,^a Gulice Yiu Chung Leung,^b Ying-Yeung Yeung*,^a

^a 3 Science Drive 3, Department of Chemistry, National University of Singapore, Singapore 117543

^b A*STAR–Institute of Chemical & Engineering Science, 11 Biopolis Way, Helios, #03-08, Singapore 138667


E-mail: chmyyy@nus.edu.sg; Fax: +65-6779-1691; Tel: +65-6516-7760

Table of contents

S2-S30	Experimental procedures and physical data
S31-S33	Tables S1–S3
S33	References
S34-S107	¹H and ¹³C spectra
S108-S109	Figures S1 and S2


(A) General. All reactions that required anhydrous conditions were carried by standard procedures under nitrogen atmosphere. Commercially available reagents were used as received. The solvents were dried by distillation over the appropriate drying reagents. Infrared spectra were recorded on a BIO-RAD FTS 165 FT-IR spectrophotometer and reported in wave numbers (cm^{-1}). Melting points were determined on a BÜCHI B-540b melting point apparatus. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker ACF300 (300 MHz), Bruker DPX300 (300 MHz) or AMX500 (500 MHz) spectrometer. Chemical shifts (δ) are reported in ppm relative to TMS (δ 0.00) for the ^1H NMR and to chloroform (δ 77.0) for the ^{13}C NMR measurements. Low resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI mode. High resolution mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer. Enantiomeric excesses were determined by HPLC analysis on Shimadzu HPLC units, including the following instruments: pump, LC-20AD; detector, SPD-20A; column, Daicel Chiralpak IA, IB or IC. Optical rotations were recorded on a Jasco DIP-1000 polarimeter. Analytical thin layer chromatography (TLC) was performed with Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm. Flash chromatography separations were performed on Merk 60 (0.040-0.063 mm) mesh silica gel.

(B) Catalysts 6a-6n were synthesized according to the report procedure.¹




Amino-thiocabamate 6e

72%; light yellow solid, $[\alpha]_D^{28} +155.9$ (*c* 1.0, CH₂Cl₂); IR (KBr): 2939, 1618, 1524, 1307, 1209, 1161 cm⁻¹; ¹H NMR (the compound existed as a mixture of rotamers and the major rotamer was assigned) (300 MHz, CDCl₃): δ 8.70 (d, *J* = 4.1 Hz, 1H), 8.50-8.45 (m, 1H), 7.98 (d, *J* = 9.1 Hz, 1H), 7.50-7.29 (m, 5H), 6.45 (s, 2H), 5.85-5.77 (m, 1H), 4.97-4.94 (m, 2H), 4.78-4.63 (m, 1H), 3.80 (s, 6H), 3.46-3.42 (m, 1H), 3.20-3.01 (m, 2H), 2.69-2.49 (m, 2H), 2.18-2.04 (m, 1H), 1.90-1.52 (m, 5H), 1.39 (d, *J* = 3.5 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 188.0, 158.6, 155.9, 151.9, 147.1, 144.5, 141.7, 131.5, 127.1, 124.6, 123.1, 122.9, 119.4, 118.9, 114.3, 103.9, 103.5, 98.7, 81.7, 70.0, 59.8, 56.6, 55.4, 42.5, 39.6, 27.5, 24.1, 21.8; HRMS (ESI) calcd for C₃₁H₃₈N₃O₄S *m/z* [M + H]⁺: 548.2578; found: 548.2597.




Amino-thiocabamate 6f

69%; light yellow solid, $[\alpha]_D^{28} +72.6$ (*c* 1.0, CH₂Cl₂); IR (KBr): 2941, 1639, 1526, 1209, 1159, 1034 cm⁻¹; ¹H NMR (the compound existed as a mixture of rotamers and the major rotamer was assigned) (400 MHz, CDCl₃): δ 8.90 (brs, 1H), 8.71 (d, *J* = 4.5 Hz, 1H), 7.99 (d, *J* = 9.2 Hz, 1H), 7.48-7.28 (m, 5H), 6.43 (s, 2H), 5.79-5.72 (m, 1H), 4.97-4.94 (m, 2H), 3.77-3.62 (m, 8H), 3.41-3.39 (m, 1H), 3.13-3.01 (m, 2H), 2.67-2.57 (m, 2H), 2.28-2.15 (m, 1H), 1.84-1.42 (m, 5H), 1.07 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 186.2, 158.2, 154.6, 152.3, 147.8, 143.8, 141.9, 129.0, 127.9, 127.3, 126.3, 126.0, 114.2, 113.0, 103.9, 98.8, 91.2, 81.7, 60.0, 59.1, 55.5, 42.5, 42.2, 39.8, 27.7, 27.6, 24.1; HRMS (ESI) calcd for C₄₇H₄₆N₃O₄S *m/z* [M + H]⁺: 748.3204; found: 748.3231.




Amino-thiocabamate 6g

73%; light yellow solid, $[\alpha]_D^{28} +149.4$ (*c* 1.6, CH₂Cl₂); IR (KBr): 2951, 1619, 1513, 462, 1209, 1160, 1034 cm⁻¹; ¹H NMR (the compound existed as a mixture of rotamers and the major rotamer was assigned) (400 MHz, CDCl₃): δ 8.71 (d, *J* = 4.3 Hz, 1H), 8.44 (br, 1H), 7.98 (d, *J* = 9.2 Hz, 1H), 7.64-7.31 (m, 5H), 6.47-6.44 (m, 2H), 5.83-5.77 (m, 1H), 5.00-4.95 (m, 2H), 4.16-4.01 (m, 2H), 3.86-3.68 (m, 6H), 3.45-3.42 (m, 1H), 3.14-2.99 (m, 2H), 2.62-2.56 (m, 2H), 2.24-2.15 (m, 1H), 1.92-1.43 (m, 8H), 0.99 (d, *J* = 6.5 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 188.1, 158.6, 157.3, 151.9, 147.2, 144.7, 143.0, 141.8, 131.5, 127.2, 124.6, 122.3, 119.4, 119.3, 114.3, 103.9, 103.4, 102.6, 98.7, 81.7, 66.8, 59.7, 56.5, 55.5, 42.5, 39.7, 37.8, 27.5, 25.1, 24.1, 22.6; HRMS (ESI) calcd for C₃₃H₄₂N₃O₄S *m/z* [M + H]⁺: 576.2891; found: 576.2935.




Amino-thiocabamate 6h

78%; light yellow solid, $[\alpha]_D^{28} +149.4$ (*c* 1.6, CH₂Cl₂); IR (KBr): 2957, 1620, 1525, 1466, 1215, 1037 cm⁻¹; ¹H NMR (the compound existed as a mixture of rotamers and the major rotamer was assigned) (400 MHz, CDCl₃): δ 8.90 (brs, 1H), 8.71 (d, *J* = 4.5 Hz, 1H), 7.99 (d, *J* = 9.2 Hz, 1H), 7.48-7.28 (m, 5H), 6.43 (s, 2H), 5.79-5.72 (m, 1H), 4.97-4.94 (m, 2H), 3.77-3.62 (m, 8H), 3.41-3.39 (m, 1H), 3.13-3.01 (m, 2H), 2.67-2.57 (m, 2H), 2.28-2.15 (m, 1H), 1.84-1.42 (m, 5H), 1.07 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ 188.0, 170.8, 158.6, 157.6, 152.3, 146.9, 144.4, 143.0, 141.5, 131.1, 126.8, 125.1, 122.1, 119.1, 114.1, 103.8, 102.4, 98.6, 81.2, 78.0, 60.1, 59.2, 56.3, 55.2, 42.4, 39.4, 31.7, 27.3, 26.4, 23.6; HRMS (ESI) calcd for C₃₃H₄₂N₃O₄S *m/z* [M + H]⁺: 576.2891; found: 576.2913.



Amino-thiocabamate 6i

75%; light yellow solid, $[\alpha]_D^{28} -150.2$ (c 0.9, CH_2Cl_2); IR (KBr): 2953, 1620, 1525, 1463, 1209, 1036 cm^{-1} ; ^1H NMR (the compound existed as a mixture of rotamers and the major rotamer was assigned) (300 MHz, CDCl_3): δ 8.76-8.72 (m, 2H), 8.00 (d, $J = 9.2$ Hz, 1H), 7.62-7.56 (m, 1H), 7.41-7.30 (m, 4H), 6.54-6.44 (m, 2H), 6.13-5.92 (m, 1H), 5.25-5.06 (m, 2H), 3.81-3.67 (m, 8H), 3.42-3.39 (m, 1H), 2.92-2.76 (m, 4H), 2.26-2.00 (m, 2H), 1.81-1.77 (m, 1H), 1.56-1.52 (m, 3H), 1.10 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3): δ 187.9, 157.6, 151.6, 147.0, 144.4, 143.4, 140.2, 131.1, 127.3, 124.3, 123.4, 122.2, 119.3, 118.4, 114.5, 103.8, 102.5, 98.6, 80.4, 78.0, 60.1, 59.7, 55.3, 49.1, 40.0, 31.7, 27.8, 26.5, 26.2, 24.0; HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{42}\text{N}_3\text{O}_4\text{S}$ m/z $[\text{M} + \text{H}]^+$: 576.2891; found: 576.2903.




(C) General procedure for the preparation of olefinic amide **1**

To a solution of acid **A** (1.0 mmol, 1.0 eq) (synthesized according to the literature procedure³) in THF (10 mL) was added LiAlH₄ (76 mg, 2.0 mmol, 2.0 eq) at 0 °C under N₂. The resulting mixture was stirred at 0 °C for 10 min and then was warmed to 25 °C and stirred for another 3 h. After TLC revealed the absence of the starting material, the reaction was quenched with crushed ice. The mixture was filtered through a thin pad of silica gel and eluted with EtOAc (20 mL). The filtrate was concentrated *in vacuo*, which was used directly without further purification, or purified by a short column (hexane/EtOAc 3:1) to give alcohol **B**.

To a solution of alcohol **B** (1.0 mmol, 1.0 eq) and triethylamine (418 μL, 3.0 mmol, 3.0 eq) in CH₂Cl₂ (5 mL) was added MsCl (116 μL, 1.5 mmol, 1.5 eq) at 0 °C. The resulting mixture was stirred at 0 °C for 10 min and then was warmed to 25 °C and stirred for another 2 h. After TLC revealed the absence of the starting material, the reaction was quenched with water (4 mL) and extracted with CH₂Cl₂ (3 × 5 mL). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography (hexane/EtOAc 3:1) to give the compound **C**.


A modified literature² procedure was used for the direct conversion of Ms-activated alcohols to the corresponding 4-nitrobenzenesulfonamides. A solution of compound **C** (1.0 mmol, 1.0 eq), NsNH₂ (404 mg, 2.0 mmol, 2.0 eq) and K₂CO₃ (276 mg, 2.0 mmol, 2.0 eq) in DMF (5 mL) was stirred at 90 °C for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with Et₂O (3 × 15 mL). The combined organic extracts were washed with water (3 × 10 mL) and brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography (CH₂Cl₂/hexane 2:1 to pure CH₂Cl₂) to give the product **1**.



(E)-4-Nitro-N-(5-phenylpent-4-enyl)benzenesulfonamide (**1a**)


Yellow solid, IR (KBr): 3259, 3103, 1546, 1350, 1160, 1061 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.30 (d, *J* = 8.8 Hz, 2H), 8.05 (d, *J* = 9.0 Hz, 2H), 7.29-7.19 (m, 5H), 6.34 (d, *J* = 15.8 Hz, 1H), 6.08 (dt, *J* = 15.8, 6.9 Hz, 1H), 5.18 (t, *J* = 5.8 Hz, 1H), 3.06 (dt, *J* = 6.7 Hz, 2H), 2.23 (dt, *J* = 6.9 Hz, 2H), 1.74-1.65 (m,

2H); ^{13}C NMR (75 MHz, CDCl_3): δ 149.9, 145.7, 137.0, 131.1, 128.5, 128.4, 128.2, 127.2, 125.8, 124.3, 42.6, 29.6, 29.0; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 345.0915; found: 345.0920.




(E)-N-[5-(4-Fluorophenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1b)

Yellow solid, IR (KBr): 3258, 1531, 1351, 1307, 1162, 1091 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 8.32 (d, J = 8.2 Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 7.23 (dd, J = 8.2, 5.7 Hz, 2H), 6.96 (dd, J = 8.5 Hz, 2H), 6.29 (d, J = 15.8 Hz, 1H), 5.98 (dt, J = 15.1, 6.9 Hz, 1H), 5.06 (t, J = 5.8 Hz, 1H), 3.06 (dt, J = 6.3 Hz, 2H), 2.21 (dt, J = 7.0 Hz, 2H), 1.71-1.65 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 162.0 (d, J = 245.0 Hz), 150.0, 145.8, 133.3 (d, J = 3.6 Hz), 130.0, 128.2, 128.2 (d, J = 1.8 Hz), 127.3 (d, J = 7.3 Hz), 124.4, 115.4 (d, J = 21.9 Hz), 42.7, 29.6, 29.1; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{FN}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 363.0820; found: 363.0813.




(E)-N-[5-(4-Chlorophenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1c)

Yellow solid, IR (KBr): 3278, 1530, 1350, 1314, 1164, 1088 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 8.34 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 7.21 (d, J = 8.6 Hz, 2H), 6.30 (d, J = 15.8 Hz, 1H), 6.07 (dt, J = 15.8, 6.9 Hz, 1H), 4.69 (t, J = 6.0 Hz, 1H), 3.08 (dt, J = 6.9 Hz, 2H), 2.23 (dt, J = 6.4 Hz, 2H), 1.73-1.58 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 150.1, 145.9, 135.6, 132.9, 130.2, 129.1, 128.7, 128.3, 127.2, 124.4, 42.8, 29.7, 29.2; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClN}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 379.0525; found: 379.0516.




(E)-N-[5-(4-Bromophenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1d)

Yellow solid, IR (KBr): 3279, 1529, 1412, 1349, 1163, 1050 cm^{-1} ; ^1H NMR (300 MHz, $\text{Acetone-}d_6$): δ 8.42 (dd, J = 9.0 Hz, 2H), 8.13 (d, J = 9.0 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 6.90 (brs, 1H), 6.37 (d, J = 16.1 Hz, 1H), 6.26 (dt, J = 15.8, 6.3 Hz, 1H), 3.06 (dt, J = 6.8 Hz, 2H), 2.24 (dt, J = 7.1 Hz, 2H), 1.74-1.65 (m, 2H); ^{13}C NMR (125 MHz, $\text{Acetone-}d_6$): δ 149.8, 146.6, 136.7, 131.2, 130.3, 129.1, 128.1, 127.5, 124.1, 119.8, 42.2, 29.5, 29.0; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{BrN}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 423.0020; found: 423.0016.




(E)-N-[5-(4-methoxyphenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1e)

Yellow solid, IR (KBr): 3282, 1529, 1349, 1240, 1165, 1041 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 8.31 (d, J = 9.0 Hz, 2H), 7.83 (d, J = 9.0 Hz, 2H), 7.22-7.17 (m, 2H), 6.82 (dd, J = 6.8, 2.0 Hz, 2H), 6.26 (d, J = 15.8 Hz, 1H), 5.91 (dt, J = 15.6, 6.9 Hz, 1H), 4.91 (t, J = 6.0 Hz, 1H), 3.80 (s, 3H), 3.05 (dt, J = 6.9 Hz, 2H), 2.20 (dt, J = 7.0 Hz, 2H), 1.72-1.62 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ 158.9, 150.0, 145.8, 130.6, 128.2, 127.0, 126.1, 126.0, 124.3, 113.9, 55.3, 42.6, 29.7, 29.2; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_5\text{S}$ m/z $[\text{M} - \text{H}]^-$: 375.1020; found: 375.1018.




(E)-N-[5-(3-Chlorophenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1f)

Yellow solid, IR (KBr): 32608, 1534, 1351, 1310, 1160, 1091 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.29 (d, J = 8.9 Hz, 2H), 8.01 (d, J = 9.0 Hz, 2H), 7.23-7.08 (m, 4H), 6.24 (d, J = 15.9 Hz, 1H), 6.05 (dt, J = 15.8, 6.9 Hz, 1H), 4.97 (t, J = 6.1 Hz, 1H), 3.02 (dt, J = 6.9 Hz, 2H), 2.19 (dt, J = 7.3, 1.2 Hz, 2H), 1.69-1.61 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 150.0, 145.8, 139.0, 134.4, 130.0, 129.9, 129.7, 128.2, 127.1, 125.8, 124.4, 124.2, 42.6, 29.6, 29.0; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClN}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 379.0525; found: 379.0529.



(E)-4-Nitro-N-(5-m-tolylpent-4-enyl)benzenesulfonamide (1g)


Yellow solid, IR (KBr): 3280, 1530, 1413, 1351, 1162, 1049 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.30 (d, J = 9.0 Hz, 2H), 8.04 (d, J = 9.0 Hz, 2H), 7.17 (d, J = 7.5 Hz, 1H), 7.09-7.02 (m, 3H), 6.29 (d, J = 15.8 Hz, 1H), 6.06 (dt, J = 15.8, 6.9 Hz, 1H), 5.17 (t, J = 6.0 Hz, 1H), 3.06 (dt, J = 6.9 Hz, 2H), 2.33 (s, 3H), 2.22 (dt, J = 6.4, 1.1 Hz, 2H), 1.70-1.67 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 149.9, 145.7, 138.0, 137.0, 131.2, 128.4, 128.2, 128.1, 128.0, 126.6, 124.3, 123.0, 42.6, 29.6, 29.0, 21.3; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 359.1071; found: 359.1076.



(E)-N-[5-(4-methoxyphenyl)pent-4-enyl]-4-nitrobenzenesulfonamide (1h)


Yellow solid, IR (KBr): 3264, 1533, 1349, 1162, 1090 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 8.31 (d, J = 8.9 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 7.20 (dd, J = 7.7 Hz, 1H), 6.88-6.74 (m, 3H), 6.30 (d, J = 15.9 Hz,

1H), 6.06 (dt, $J = 15.7, 6.9$ Hz, 1H), 4.97 (t, $J = 6.1$ Hz, 1H), 3.80 (s, 3H), 3.05 (dt, $J = 6.9$ Hz, 2H), 2.22 (dt, $J = 6.9$ Hz, 2H), 1.73-1.63 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ 159.7, 150.0, 145.8, 138.5, 131.1, 129.5, 128.7, 128.2, 124.4, 118.6, 112.6, 111.5, 55.2, 42.6, 29.6, 29.0; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_5\text{S}$ m/z $[\text{M} - \text{H}]^-$: 375.1020; found: 375.1012.




(E)-N-[5-(naphthalen-2-yl)-pent-4-enyl]-4-nitrobenzenesulfonamide (1i)

Yellow solid, IR (KBr): 3255, 1532, 1349, 1309, 1159, 1061 cm^{-1} ; δ ^1H NMR (300 MHz, Acetone- d_6): δ 8.42 (d, $J = 8.9$ Hz, 2H), 8.15 (d, $J = 8.9$ Hz, 2H), 7.84-7.79 (m, 3H), 7.72 (s, 1H), 7.61 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.50-7.40 (m, 2H), 6.92 (t, $J = 5.6$ Hz, 1H), 6.56 (d, $J = 15.8$ Hz, 1H), 6.37 (dt, $J = 15.8, 6.9$ Hz, 1H), 3.10 (dt, $J = 6.8$ Hz, 2H), 2.30 (dt, $J = 6.9$ Hz, 2H), 1.78-1.68 (m, 2H); ^{13}C NMR (75 MHz, Acetone- d_6): δ 149.8, 146.6, 135.0, 133.6, 132.6, 130.5, 129.7, 128.1, 127.8, 127.6, 127.4, 126.0, 125.4, 125.2, 124.2, 123.2, 42.3, 29.5, 29.0; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$ m/z $[\text{M} - \text{H}]^-$: 395.1071; found: 395.1078.



(E)-4-nitro-N-[5-(thiophen-3-yl)pent-4-enyl]benzenesulfonamide (1j)


Yellow solid, IR (KBr): 3254, 1546, 1349, 1159, 1063, 967 cm^{-1} ; δ ^1H NMR (300 MHz, CDCl_3): δ 8.28 (d, $J = 8.9$ Hz, 2H), 8.00 (d, $J = 9.0$ Hz, 2H), 7.22-7.19 (m, 1H), 7.07 (dd, $J = 4.9, 1.0$ Hz, 1H), 6.99 (dd, $J = 3.0, 1.1$ Hz, 1H), 6.30 (d, $J = 15.8$ Hz, 1H), 5.88 (dt, $J = 15.8, 6.9$ Hz, 1H), 4.98 (t, $J = 6.1$ Hz, 1H), 3.01 (dt, $J = 6.9$ Hz, 2H), 2.15 (ddd, $J = 8.4, 7.2, 1.3$ Hz, 2H), 1.69-1.58 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3): δ 150.0, 145.8, 139.7, 128.3, 128.2, 126.0, 125.5, 124.7, 124.4, 121.0, 42.6, 29.5, 29.1; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_4\text{S}_2$ m/z $[\text{M} - \text{H}]^-$: 351.0479; found: 351.0461.



(E)-4-nitro-N-[5-(thiophen-2-yl)pent-4-enyl]benzenesulfonamide (1k)


Yellow solid, IR (KBr): 3249, 1531, 1348, 1310, 1159, 1065 cm^{-1} ; δ ^1H NMR (300 MHz, CDCl_3): δ 8.33 (d, $J = 9.0$ Hz, 2H), 8.04 (d, $J = 9.1$ Hz, 2H), 7.10 (d, $J = 5.1$ Hz, 1H), 6.92 (dd, $J = 5.1, 3.5$ Hz, 1H), 6.83 (d, $J = 3.3$ Hz, 1H), 6.45 (d, $J = 15.6$ Hz, 1H), 5.89 (dt, $J = 15.6, 7.1$ Hz, 1H), 4.86 (t, $J = 5.8$ Hz, 1H), 3.05 (dt, $J = 6.7$ Hz, 2H), 2.19 (ddd, $J = 8.4, 7.1, 1.1$ Hz, 2H), 1.72-1.62 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 150.0, 145.8, 142.2, 128.3, 128.2, 127.3, 124.8, 124.5, 124.4, 123.6, 42.6, 29.5, 29.0; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_4\text{S}_2$ m/z $[\text{M} - \text{H}]^-$: 351.0479; found: 351.0461.

(D) General Procedure for the Bromoamidation. To a solution of olefinic amide **1** (0.1 mmol, 1.0 equiv), catalyst **6h** (0.01 mmol, 0.1 equiv) in the corresponding solvent (0.02 M) at corresponding temperature in dark under N₂ was added brominating source (0.12 mmol, 1.2 equiv). The resulting mixture was stirred at that temperature and monitored by TLC. The reaction was quenched with saturated Na₂SO₃ (2.0 mL) and then was warmed to 25 °C. The solution was diluted with water (3.0 mL) and extracted with CH₂Cl₂ (3 × 5 mL). The combined extracts were washed with brine (5.0 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel (CH₂Cl₂/hexane 2:1) to yield the corresponding piperidine **2**.




(2S,3R)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-phenylpiperidine (2a)

White solid, $[\alpha]_D^{26} -17.6$ (*c* 1.4, CH₂Cl₂, 90% ee); IR (KBr): 2939, 1526, 1349, 1312, 1160, 1108 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.31 (d, *J* = 8.8 Hz, 2H), 8.06 (d, *J* = 9.0 Hz, 2H), 7.39-7.29 (m, 5H), 5.51 (s, 1H), 4.97 (d, *J* = 2.6 Hz, 1H), 3.90 (d, *J* = 15.7 Hz, 1H), 3.33 (ddd, *J* = 15.2, 12.2, 2.9 Hz, 1H), 2.04-1.81 (m, 3H), 1.52-1.48 (m, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 149.9, 146.2, 136.9, 129.1, 128.8, 128.0, 126.7, 123.9, 63.8, 51.5, 42.2, 27.2, 19.5; HRMS (EI) calcd for C₁₇H₁₇BrN₂O₄S *m/z* [M]⁺: 424.0087; found: 424.0080. HPLC (Daicel Chiralpak IC, *i*-PrOH/hexane = 45/55, 0.6 mL/min, 230 nm) *t*₁ = 43.9 min (major), *t*₂ = 48.5 min (minor).




Detector A Ch1 230nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	44.347	5572945	83852	49.970	52.951
2	48.499	5579747	74507	50.030	47.049
Total		11152693	158358	100.000	100.000




Detector A Ch1 230nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	43.894	15566957	222857	94.968	95.368
2	48.464	824771	10825	5.032	4.632
Total		16391728	233682	100.000	100.000




(2R,3S)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-phenylpiperidine (ent-2a)

$[\alpha]_D^{26} +22.4$ (c 1.0, CH_2Cl_2 , 99% ee);




Detector A Ch1 230nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	44.347	5572945	83852	49.970	52.951
2	48.499	5579747	74507	50.030	47.049
Total		11152693	158358	100.000	100.000





Detector A Ch1 230nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	43.533	26034	436	0.109	0.142
2	46.904	23883000	306229	99.891	99.858
Total		23909034	306665	100.000	100.000



(2S,3R)-3-Bromo-2-(4-fluorophenyl)-1-(4-nitrophenylsulfonyl)piperidine (2b)



White solid, $[\alpha]_D^{26} -12.6$ (c 1.0, CH_2Cl_2 , 83% ee); IR (KBr): 2962, 1605, 1531, 1347, 1164, 1010 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 8.34 (d, $J = 9.0$ Hz, 2H), 8.04 (d, $J = 9.1$ Hz, 2H), 7.34-7.29 (m, 2H), 7.07 (dd, $J = 8.5$ Hz, 2H), 5.47 (s, 1H), 4.93 (dd, $J = 5.4, 2.3$ Hz, 1H), 3.86 (dd, $J = 14.3, 2.9$ Hz, 1H), 3.30 (ddd, $J = 14.2, 12.2, 3.0$ Hz, 1H), 1.95-1.83 (m, 3H), 1.54-1.48 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 162.2 (d, $J = 247.1$), 150.0, 146.0, 132.6, 128.8, 128.5 (d, $J = 7.6$ Hz), 124.0, 116.1 (d, $J = 21.8$), 63.3, 51.2, 42.1, 27.2, 19.4; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{16}\text{FBrN}_2\text{O}_4\text{S}$ m/z $[\text{M}]^+$: 441.9993; found: 441.9992. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 45/55, 0.6 mL/min, 230 nm) $t_1 = 32.3$ min (major), $t_2 = 34.4$ min (minor).






(2S,3R)-3-Bromo-2-(4-chlorophenyl)-1-(4-nitrophenylsulfonyl)piperidine (2c)



White solid, $[\alpha]_D^{26} -15.4$ (c 0.57, CH_2Cl_2 , 73% ee); IR (KBr): 2958, 1607, 1530, 1346, 1162, 1108 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 8.34 (d, $J = 8.8$ Hz, 2H), 8.10 (d, $J = 8.2$ Hz, 2H), 7.36 (d, $J = 8.2$ Hz, 2H), 7.28 (d, $J = 8.2$ Hz, 2H), 5.46 (s, 1H), 4.92 (d, $J = 3.2$ Hz, 1H), 3.86 (d, $J = 12.6$ Hz, 1H), 3.29 (ddd, $J = 14.5, 12.0, 3.2$ Hz, 1H), 1.92-1.82 (m, 3H), 1.55-1.48 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 150.0, 146.0, 135.4, 134.1, 129.3, 128.8, 128.2, 124.0, 63.3, 51.0, 42.2, 27.3, 19.4; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClBrN}_2\text{O}_4\text{S}$ m/z $[\text{M}]^+$: 457.9697; found: 457.9693. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 45/55, 0.6 mL/min, 230 nm) $t_1 = 31.0$ min (major), $t_2 = 33.9$ min (minor).






(2S,3R)-3-Bromo-2-(4-bromophenyl)-1-(4-nitrophenylsulfonyl)piperidine (2d)



White solid, $[\alpha]_D^{25} -17.4$ (*c* 1.0, CH₂Cl₂, 72% ee); IR (KBr): 2927, 1523, 1489, 1350, 1160, 1109 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 8.34 (d, *J* = 8.7 Hz, 2H), 8.10 (d, *J* = 8.7 Hz, 2H), 7.51 (d, *J* = 8.5 Hz, 2H), 7.22 (d, *J* = 8.5 Hz, 2H), 5.43 (s, 1H), 4.92 (d, *J* = 2.5 Hz, 1H), 3.86 (d, *J* = 13.3 Hz, 1H), 3.29 (ddd, *J* = 14.9, 12.2, 2.8 Hz, 1H), 1.93-1.79 (m, 3H), 1.51-1.25 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 150.1, 146.0, 136.0, 132.3, 128.9, 128.5, 124.0, 122.2, 63.4, 50.9, 42.2, 27.4, 19.5; HRMS (EI) calcd for C₁₇H₁₆Br₂N₂O₄S *m/z* [M]⁺: 501.9192; found: 501.9200. HPLC (Daicel Chiralpak IC, *i*-PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) *t*₁ = 35.4 min (major), *t*₂ = 39.0 min (minor).






(2S,3R)-3-Bromo-2-(4-methoxyphenyl)-1-(4-nitrophenylsulfonyl)piperidine (2e)



White solid, $[\alpha]_D^{25} -4.0$ (c 0.5, CH_2Cl_2 , 34% ee); IR (KBr): 2954, 1607, 1525, 1351, 1162, 1107 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 8.32 (d, $J = 8.8$ Hz, 2H), 8.04 (d, $J = 8.9$ Hz, 2H), 7.34 (d, $J = 1.9$ Hz, 1H), 7.26 (s, 1H), 6.87 (d, $J = 8.8$ Hz, 1H), 5.40 (s, 1H), 4.85 (dd, $J = 5.6, 2.9$ Hz, 1H), 3.89 (s, 3H), 3.89-3.86 (m, 1H), 3.30 (ddd, $J = 14.4, 11.4, 2.6$ Hz, 1H), 1.97-1.87 (m, 4H), 1.55-1.42 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3): δ 155.5, 150.0, 146.0, 131.6, 130.2, 128.7, 127.3, 124.0, 112.2, 112.1, 62.9, 56.3, 51.0, 42.3, 27.3, 19.6; HRMS (EI) calcd for $\text{C}_{18}\text{H}_{19}\text{BrN}_2\text{O}_5\text{S}$ m/z $[\text{M}]^+$: 454.0193; found: 454.0190. HPLC (Daicel Chiralpak IB, i -PrOH/hexane = 45/55, 0.6 mL/min, 230 nm) $t_1 = 20.8$ min (major), $t_2 = 22.3$ min (minor).






(2S,3R)-3-Bromo-2-(3-chlorophenyl)-1-(4-nitrophenylsulfonyl)piperidine (2f)



White solid, $[\alpha]_D^{25}$ -24.2 (c 1.0, CH_2Cl_2 , 90% ee); IR (KBr): 2928, 1526, 1346, 1160, 1108, 951 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.33 (d, $J = 8.9$ Hz, 2H), 8.07 (d, $J = 8.9$ Hz, 2H), 7.34-7.28 (m, 2H), 7.26-7.21 (m, 2H), 5.46 (s, 1H), 4.90 (dd, $J = 5.6, 2.8$ Hz, 1H), 3.90 (dd, $J = 13.8, 2.8$ Hz, 1H), 3.31 (ddd, $J = 13.9, 12.0, 2.9$ Hz, 1H), 2.04-1.82 (m, 3H), 1.55-1.50 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 150.0, 145.9, 139.0, 135.2, 130.5, 128.8, 128.3, 127, 125.0, 124.1, 63.3, 50.8, 42.3, 27.3, 19.4; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{16}\text{ClBrN}_2\text{O}_4\text{S}$ m/z $[\text{M}]^+$: 457.9697; found: 457.9693. HPLC (Daicel Chiralpak AD, i -PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) $t_1 = 19.4$ min (minor), $t_2 = 23.6$ min (major).






(2S,3R)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-*p*-tolylpiperidine (2g)



White solid, $[\alpha]_D^{25} -17.5$ (*c* 1.0, CH₂Cl₂, 88% ee); IR (KBr): 2927, 1526, 1346, 1160, 1108 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 8.30 (d, *J* = 8.8 Hz, 2H), 8.05 (d, *J* = 8.8 Hz, 2H), 7.23 (dd, *J* = 7.7 Hz, 1H), 7.09 (d, *J* = 8.5 Hz, 2H), 7.04 (s, 1H), 5.47 (s, 1H), 4.95 (dd, *J* = 5.6, 2.9 Hz, 1H), 3.90 (dd, *J* = 14.0, 2.9 Hz, 1H), 3.35 (ddd, *J* = 14.8, 12.0, 3.1 Hz, 1H), 2.32 (s, 3H), 1.98-1.83 (m, 3H), 1.53-1.49 (m, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 149.8, 146.2, 138.9, 136.8, 129.0, 128.8, 128.7, 127.4, 123.9, 123.8, 63.8, 51.7, 42.3, 27.2, 21.6, 19.5; HRMS (EI) calcd for C₁₈H₁₉BrN₂O₄S *m/z* [M]⁺: 438.0243; found: 438.0233. HPLC (Daicel Chiralpak IA, *i*-PrOH/hexane = 15/85, 0.6 mL/min, 230 nm) *t*₁ = 21.6 min (minor), *t*₂ = 22.6 min (major).






(2S,3R)-3-Bromo-2-(3-methoxyphenyl)-1-(4-nitrophenylsulfonyl)piperidine (2h)



White solid, $[\alpha]_D^{25} -11.8$ (c 1.0, CH_2Cl_2 , 86% ee); IR (KBr): 3021, 1531, 1349, 1216, 1164 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.30 (d, $J = 9.0$ Hz, 2H), 8.02 (d, $J = 9.0$ Hz, 2H), 7.29-7.25 (m, 1H), 6.88-6.80 (m, 3H), 5.48 (s, 1H), 4.95 (dd, $J = 5.5, 2.9$ Hz, 1H), 3.88 (dd, $J = 13.8, 2.8$ Hz, 1H), 3.78 (s, 3H), 3.33 (ddd, $J = 13.9, 12.0, 2.9$ Hz, 1H), 1.99-1.86 (m, 3H), 1.53-1.49 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 160.2, 149.9, 146.1, 138.5, 130.2, 128.8, 123.9, 118.9, 113.2, 112.8, 63.7, 55.3, 51.5, 42.3, 27.2, 19.4; HRMS (EI) calcd for $\text{C}_{18}\text{H}_{19}\text{BrN}_2\text{O}_5\text{S}$ m/z $[\text{M}]^+$: 454.0193; found: 454.0190. HPLC (Daicel Chiralpak IA, i -PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) $t_1 = 19.0$ min (minor), $t_2 = 20.3$ min (major).






(2*S*,3*R*)-3-Bromo-2-(naphthalen-2-yl)-1-(4-nitrophenylsulfonyl)piperidine (2i)



White solid, $[\alpha]_D^{25}$ -19.6 (c 1.0, CH_2Cl_2 , 72% ee); IR (KBr): 2943, 1532, 1351, 1310, 1161, 1107 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.25 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 7.85-7.82 (m, 2H), 7.73 (d, J = 5.8 Hz, 1H), 7.67 (s, 1H), 7.53-7.48 (m, 2H), 7.41 (dd, J = 8.6, 1.8 Hz, 1H), 5.64 (s, 1H), 5.90 (dd, J = 5.8, 2.8 Hz, 1H), 3.96 (d, J = 13.7 Hz, 1H), 3.47 (ddd, J = 13.8, 11.0, 3.0 Hz, 1H), 2.04-1.91 (m, 3H), 1.57-1.53 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 149.9, 146.2, 134.2, 133.1, 132.6, 129.1, 128.8, 128.0, 127.6, 126.78, 126.76, 126.2, 124.3, 123.9, 64.1, 51.4, 52.6, 27.5, 19.7; HRMS (EI) calcd for $\text{C}_{21}\text{H}_{19}\text{BrN}_2\text{O}_4\text{S}$ m/z $[\text{M}]^+$: 474.0243; found: 474.0233. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) t_1 = 47.6 min (major), t_2 = 56.6 min (minor).






(2S,3R)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-(thiophen-3-yl)piperidine (2j)


White solid, $[\alpha]_D^{25} -17.8$ (c 0.5, CH_2Cl_2 , 83% ee); IR (KBr): 2960, 1525, 1344, 1168, 1093 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.32 (d, $J = 8.8$ Hz, 2H), 8.08 (d, $J = 8.9$ Hz, 2H), 7.34 (dd, $J = 5.0, 2.9$ Hz, 1H), 7.17-7.16 (m, 1H), 7.02 (d, $J = 5.0$ Hz, 1H), 5.51 (s, 1H), 4.87 (brs, 1H), 3.78 (d, $J = 13.0$ Hz, 1H), 3.24 (ddd, $J = 13.9, 12.0, 2.7$ Hz, 1H), 1.99-1.88 (m, 3H), 1.54-1.48 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 149.9, 146.0, 138.1, 128.8, 127.1, 126.4, 124.0, 123.0, 61.0, 50.8, 41.7, 27.4, 19.5; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{15}\text{BrN}_2\text{O}_4\text{S}_2$ m/z $[\text{M}]^+$: 429.9651; found: 429.9654. HPLC (Daicel Chiralpak IB, i -PrOH/hexane = 30/70, 0.6 mL/min, 230 nm) $t_1 = 24.0$ min (minor), $t_2 = 25.5$ min (major).






(2S,3R)-3-Bromo-1-(4-nitrophenylsulfonyl)-2-(thiophen-2-yl)piperidine (2k)



White solid, $[\alpha]_D^{25} -20.2$ (c 1.0, CH_2Cl_2 , 59% ee); IR (KBr): 2944, 1532, 1350, 1162, 1092 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 8.26 (d, $J = 8.9$ Hz, 2H), 7.97 (d, $J = 8.7$ Hz, 2H), 7.23 (dd, $J = 5.1, 1.2$ Hz, 1H), 7.02 (dd, $J = 2.5, 1.2$ Hz, 1H), 6.98 (dd, $J = 5.1, 3.7$ Hz, 1H), 5.73 (s, 1H), 4.72 (d, $J = 2.3$ Hz, 1H), 3.83 (dd, $J = 13.3, 3.7$ Hz, 1H), 3.24 (ddd, $J = 13.3, 10.3, 3.0$ Hz, 1H), 2.19-2.00 (m, 3H), 1.98-1.58 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3): δ 149.9, 145.7, 139.6, 128.7, 127.1, 127.0, 125.9, 123.9, 60.5, 50.8, 41.6, 27.2, 19.4; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{15}\text{BrN}_2\text{O}_4\text{S}_2$ m/z $[\text{M}]^+$: 429.9651; found: 429.9666. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) $t_1 = 62.3$ min (major), $t_2 = 70.9$ min (minor).






(R)-1-(4-Nitrophenylsulfonyl)-6-phenyl-1,2,3,6-tetrahydropyridine (7)

White solid, $[\alpha]_D^{25} +264.6$ (c 1.0, CH_2Cl_2 , 99% ee); IR (KBr): 2932, 1532, 1346, 1163, 1097, 940 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 8.21 (d, $J = 8.9$ Hz, 2H), 7.85 (d, $J = 8.9$ Hz, 2H), 7.37-7.35 (m, 2H), 7.31-7.28 (m, 3H), 5.93-5.89 (m, 1H), 5.85-5.80 (m, 1H), 5.53 (s, 1H), 3.85 (ddd, $J = 13.8, 6.2, 1.0$ Hz, 1H), 3.15 (ddd, $J = 16.2, 11.3, 5.0$ Hz, 1H), 2.14-1.97 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 149.7, 146.9, 138.7, 128.5, 128.3 (2 carbons), 128.2, 128.1, 126.0, 124.0, 56.6, 38.7, 23.8; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_4\text{S}$ m/z $[\text{M}]^+$: 344.0825; found: 344.0834. HPLC (Daicel Chiralpak IA, i -PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) $t_1 = 12.0$ min (minor), $t_2 = 17.0$ min (major).






(6S)-6-Phenyl-1-azabicyclo[3.1.0]hexane (8)

^1H NMR (400 MHz, CDCl_3): δ 7.29-7.18 (m, 5H), 3.20 (ddd, $J = 12.2, 8.4, 1.3$ Hz, 1H), 3.05 (dt, $J = 11.5, 7.6$ Hz, 1H), 2.44 (d, $J = 4.8, 2.8$ Hz, 1H), 2.35 (d, $J = 2.6$ Hz, 1H), 2.23 (d, $J = 13.3, 8.1$ Hz, 1H), 2.03-1.93 (m, 1H), 1.78-1.70 (m, 1H), 1.65-1.56 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 140.2, 128.2, 126.7, 126.0, 53.1, 50.6, 39.7, 26.6, 20.7; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{14}\text{N}$ m/z $[\text{M} + \text{H}]^+$: 160.1121; found: 160.1114.



(E) Representative procedure for the silver salt mediated rearrangement


A solution of **ent-2a** (85 mg, 0.2 mmol, 1.0 eq) and silver trifluoroacetate (133 mg, 0.6 mmol, 3.0 eq) in acetone (3.0 mL) and water (1.0 mL) was stirred at 60 °C for 8 h in dark. After the mixture was cooled to room temperature, to the solution was added sat. NaCl (2.0 mL) and stirred for 5 min. The mixture was filtered by celite and washed with EtOAc. The filtrate was separated and the aqueous phase was extracted with EtOAc (3 × 5 mL). The combined extracts were washed with brine, dried and concentrated in *vacuo*. The residue was purified by column chromatography to give the desired product **ent-3a** as a yellow solid (50 mg, 68%).



(2S,3S)-1-(4-nitrophenylsulfonyl)-2-phenylpiperidin-3-ol (**ent-3a**)


$[\alpha]_D^{25}$ -110.9 (*c* 1.0, CH₂Cl₂, 99% ee); IR (KBr): 3491, 2946, 1527, 1348, 1165, 1089 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.31 (d, *J* = 8.9 Hz, 2H), 8.04 (d, *J* = 8.9 Hz, 2H), 7.37-7.34 (m, 2H), 7.28-7.25 (m, 3H), 5.64 (t, *J* = 2.9 Hz, 1H), 3.69 (dt, *J* = 12.7, 2.9 Hz, 1H), 3.05-2.97 (m, 2H), 2.16-2.05 (m, 1H), 1.98-1.93 (m, 1H), 1.86-1.75 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 150.0, 145.3, 140.2, 129.1, 128.9, 128.0, 127.6, 124.0, 79.9, 47.5, 40.2, 25.1, 21.8; HRMS (ESI) calcd for C₁₇H₁₇N₂O₅S *m/z* [M - H]⁻: 361.0864; found: 361.0864. HPLC (Daicel Chiralpak IA, *i*-PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) *t*₁ = 9.0 min (major), *t*₂ = 14.0 min (minor).






(2R,3R)-3-(4-fluorophenyl)-1-(4-nitrophenylsulfonyl)piperidin-2-ol (3b)

Yellow oil. $[\alpha]_D^{25} +18$ (c 1.0, CHCl_3 , 83% ee); IR (film): 3498, 2929, 1530, 1349, 1164, 1091 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 7.25 – 7.21 (m, 2H), 7.05 (d, J = 8.6 Hz, 2H), 5.61 (s, 1H), 3.70 (d, J = 11.3 Hz, 1H), 3.04 – 2.98 (m, 2H), 2.07 (dd, J = 13.0, 3.6 Hz, 1H), 1.95 (d, J = 13.6 Hz, 1H), 1.81 – 1.73 (m, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 162.1 (d, J = 245.1 Hz), 150.1, 145.3, 136.0 (d, J = 3.1 Hz), 129.6 (d, J = 8.0 Hz), 129.0, 124.1, 115.7 (d, J = 21.1 Hz), 79.7, 46.8, 40.1, 29.7, 25.1, 22.2; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{FN}_2\text{O}_5\text{SNa}$ m/z $[\text{M} + \text{Na}]^+$: 403.0734; found: 403.0740. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 15/85, 0.6 mL/min, 230 nm) t_1 = 19.9 min (major), t_2 = 21.7 min (minor).




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.880	12584568	329695	49.660	50.152
2	21.650	12757075	327699	50.340	49.848
Total		25341643	657393	100.000	100.000




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.915	5674005	150756	91.292	89.801
2	21.742	541226	17122	8.708	10.199
Total		6215231	167878	100.000	100.000




(2R,3R)-3-(4-bromophenyl)-1-(4-nitrophenylsulfonyl)piperidin-2-ol (3d)

Yellow oil. $[\alpha]_D^{25} +27$ (c 1.0, CHCl_3 , 72% ee); IR (film): 3369, 2923, 1532, 1349, 1162, 1009 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 8.33 (d, $J = 8.8$ Hz, 2H), 8.04 (d, $J = 8.8$ Hz, 2H), 7.48 (d, $J = 8.4$ Hz, 2H), 7.14 (d, $J = 8.4$ Hz, 2H), 5.63 – 5.59 (m, 1H), 3.69 (d, $J = 11.8$ Hz, 1H), 3.02 (dd, $J = 16.9, 7.5$ Hz, 1H), 2.98 – 2.93 (m, 1H), 2.05 (dd, $J = 12.0, 4.6$ Hz, 1H), 1.95 (d, $J = 13.7$ Hz, 1H), 1.82 – 1.73 (m, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.1, 145.3, 139.3, 132.0, 129.8, 129.0, 124.1, 121.6, 79.5, 47.1, 40.1, 24.98, 22.0; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{BrN}_2\text{O}_5\text{SNa}$ m/z $[\text{M} + \text{Na}]^+$: 462.9934; found: 462.9924. HPLC (Daicel Chiralpak IC, i -PrOH/hexane = 15/85, 0.6 mL/min, 230 nm) $t_1 = 22.9$ min (major), $t_2 = 24.7$ min (minor).




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.960	593506	14751	50.943	50.513
2	24.716	571529	14451	49.057	49.487
Total		1165035	29203	100.000	100.000




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.861	7196694	174560	86.248	86.058
2	24.662	1147452	28280	13.752	13.942
Total		8344145	202840	100.000	100.000




(2R,3R)- 1-(4-nitrophenylsulfonyl)-3-(*m*-tolyl)piperidin-2-ol (3g)

Yellow oil. $[\alpha]_D^{25} +77$ (*c* 1.0, CHCl₃, 82% ee); IR (film): 3494, 2935, 1529, 1349, 1162, 1091 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 8.31 (d, *J* = 8.8 Hz, 2H), 8.05 (d, *J* = 8.8 Hz, 2H), 7.24 (d, *J* = 7.6 Hz, 1H), 7.12 – 7.03 (m, 3H), 5.64 (s, 1H), 3.70 (d, *J* = 10.9 Hz, 1H), 2.99 (dd, *J* = 16.9, 13.1 Hz, 2H), 2.35 (s, 3H), 2.09 (dd, *J* = 13.0, 3.2 Hz, 1H), 1.95 (d, *J* = 13.7 Hz, 1H), 1.83 – 1.74 (m, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 150.0, 145.3, 140.1, 138.8, 129.2, 128.9, 128.8, 128.4, 124.8, 123.98, 79.9, 47.3, 40.2, 25.0, 21.7, 21.4; HRMS (ESI) calcd for C₁₈H₂₀N₂O₅SN_a *m/z* [M + Na]⁺: 399.0985; found: 399.0977. HPLC (Daicel Chiralpak IC, *i*-PrOH/hexane = 20/80, 0.6 mL/min, 230 nm) *t*₁ = 17.0 min (major), *t*₂ = 18.7 min (minor).




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	17.039	180878	7355	49.007	50.450
2	18.670	188208	7223	50.993	49.550
Total		369086	14578	100.000	100.000




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	17.037	5493506	193906	90.924	90.832
2	18.686	548371	19571	9.076	9.168
Total		6041877	213477	100.000	100.000




(2R,3R)- 1-(4-nitrophenylsulfonyl)-3-methoxypiperidin-2-ol (3h)

Yellow oil. $[\alpha]_D^{25} +92$ (*c* 0.2, CHCl₃, 83% ee); IR (film): 3513, 2931, 1529, 1349, 1161, 1090 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 8.32 (d, *J* = 8.8 Hz, 2H), 8.05 (d, *J* = 8.8 Hz, 2H), 7.28 (d, *J* = 7.9 Hz, 1H), 6.86 – 6.79 (m, 3H), 5.65 (s, 1H), 3.81 (s, 3H), 3.69 (d, *J* = 9.7 Hz, 1H), 3.03 – 2.96 (m, 2H), 2.09 – 2.04 (m, 1H), 1.98 – 1.91 (m, 1H), 1.83 – 1.75 (m, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 160.0, 150.0, 145.2, 141.8, 130.0, 129.1, 124.0, 120.1, 114.0, 112.7, 79.8, 55.3, 47.5, 40.2, 25.0, 21.8; HRMS (ESI) calcd for C₁₈H₂₀N₂O₆Na *m/z* [M + Na]⁺: 415.0934; found: 416.0946. HPLC (Daicel Chiralpak IC, *i*-PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) *t*₁ = 15.6 min (major), *t*₂ = 17.3 min (minor).




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.661	3077324	124814	49.888	52.561
2	17.211	3091088	112652	50.112	47.439
Total		6168412	237466	100.000	100.000




PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.659	1850243	79128	91.628	90.942
2	17.370	169053	7881	8.372	9.058
Total		2019296	87009	100.000	100.000



(R)-1-(4-nitrophenylsulfonyl)-3-phenylpiperidine (9)

$[\alpha]_D^{25} +215$ (*c* 1.0, CHCl₃, 83% ee); IR (film): 2936, 1529, 1349, 1170, 1089, 1047, 960 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): ¹H NMR (600 MHz, CDCl₃) δ 8.37 (d, *J* = 8.9 Hz, 2H), 7.93 (d, *J* = 8.9 Hz, 2H), 7.25 – 7.21 (m, 1H), 6.79 (ddd, *J* = 8.3, 2.6, 0.6 Hz, 1H), 6.75 (d, *J* = 7.6 Hz, 1H), 6.73 – 6.69 (m, 1H), 3.94 – 3.89 (m, 2H), 3.79 (s, 3H), 2.86 (tt, *J* = 11.7, 3.7 Hz, 1H), 2.35 (td, *J* = 12.0, 2.9 Hz, 1H), 2.28 (t, *J* = 11.4 Hz, 1H), 2.03 – 1.95 (m, 1H), 1.88 (ddd, *J* = 12.9, 6.4, 3.2 Hz, 1H), 1.83 – 1.74 (m, 1H), 1.45 (ddd, *J* = 25.6, 12.6, 3.9 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 159.8, 150.1, 143.6, 142.5, 129.7, 128.7, 124.3, 119.4, 113.3, 112.0, 55.2, 52.5, 46.4, 42.2, 30.3, 25.0; HRMS (ESI) calcd for C₁₈H₂₀N₂O₅SNa *m/z* [M + Na]⁺: 399.0985; found: 399.0988.




(S)-3-(3-methoxyphenyl)piperidine (10)

To a stirred solution of **9** (18 mg, 0.05 mmol, 1.0 eq) in 0.5 mL of MeCN was added thiophenol (16 μL, 0.25 mmol, 5.0 eq) followed by K₂CO₃ (35 mg, 0.25 mmol, 5.0 eq). After the reaction was stirred for 12 hours, the reaction was quenched with saturated NaHCO₃ (2 mL) and extracted with EtOAc (3 x 5 mL). The combined organic layer was dried using MgSO₄, filtered, and concentrated under reduced pressure.

$[\alpha]_D^{25} +8.0$ (*c* 1.0, MeOH, 83% ee); IR (film): 2931, 1601, 1436, 1160, 1089, 1046, 750 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 7.25 – 7.19 (m, 1H), 6.80 (d, *J* = 7.5 Hz, 1H), 6.78 – 6.71 (m, 2H), 3.80 (s, 3H), 3.25 (dd, *J* = 25.6, 11.8 Hz, 3H), 2.81 (ddd, *J* = 15.1, 11.6, 8.2 Hz, 1H), 2.77 – 2.66 (m, 2H), 2.07 – 1.99 (m, 1H), 1.92 – 1.81 (m, 1H), 1.80 – 1.70 (m, 1H), 1.62 (ddd, *J* = 16.2, 12.9, 3.9 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 159.71, 145.27, 129.50, 119.37, 113.06, 111.69, 77.21, 77.00, 76.79, 55.17, 52.43, 45.73, 42.90, 31.50, 25.68. HRMS (ESI) calcd for C₁₂H₁₈NO *m/z* [M + H]⁺: 191.1383; found: 191.1367.


(The data are in full accordance to the literature values in all aspects)⁴



(R)-1-(4-nitrophenylsulfonyl)-3-phenylpiperidine (**11**)


To a stirred solution of **ent-3a** (36 mg, 0.1 mmol, 1.0 eq) in 4 mL of CH₂Cl₂ was added triethylsilane (80 μL, 0.5 mmol, 5.0 eq) at -78°C. The mixture was added trifluoroacetic acid (38 μL, 0.5 mmol, 5.0 eq), stirred and allowed to warm up to room temperature overnight. The reaction was quenched with NaHCO₃ and extracted with CH₂Cl₂. The organic phase was dried with MgSO₄, filtered and removed under reduced pressure. The residue was purified by column chromatography to yield the desired product **11** as a yellow solid (31 mg, 91%).

$[\alpha]_D^{25}$ -18.0 (*c* 1.0, CHCl₃, 99% ee); IR (film): 2935, 1529, 1350, 1168, 1089 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): ¹H NMR (600 MHz, CDCl₃) δ 8.37 (d, *J* = 8.7 Hz, 2H), 7.93 (d, *J* = 8.7 Hz, 2H), 7.31 (t, *J* = 7.4 Hz, 2H), 7.25 (d, *J* = 7.4 Hz, 1H), 7.17 (d, *J* = 7.2 Hz, 2H), 3.92 (d, *J* = 11.5 Hz, 2H), 2.92 – 2.85 (m, 1H), 2.35 (td, *J* = 12.0, 2.5 Hz, 1H), 2.29 (t, *J* = 11.4 Hz, 1H), 1.99 (d, *J* = 13.3 Hz, 1H), 1.92 – 1.86 (m, 1H), 1.86 – 1.75 (m, 1H), 1.47 (ddd, *J* = 25.6, 12.7, 3.8 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 150.13, 142.51, 141.97, 128.72, 127.19, 127.10, 124.33, 52.59, 46.40, 42.17, 30.31, 25.04; HRMS (ESI) calcd for C₁₈H₂₀N₂O₃S *m/z* [M + Na]⁺: 367.1087; found: 367.1094. HPLC (Daicel Chiralpak IC, *i*-PrOH/hexane = 40/60, 0.6 mL/min, 230 nm) *t*₁ = 28.9 min (major), *t*₂ = 32.3 min (minor).



PDA Ch1 230nm 4nm


Peak#	Ret. Time	Area	Height	Area %	Height %
1	28.917	21092373	538388	49.934	53.501
2	32.013	21148372	467920	50.066	46.499
Total		42240744	1006308	100.000	100.000



PDA Ch1 230nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	28.891	27190421	675997	99.502	99.420
2	32.290	136141	3941	0.498	0.580
Total		27326562	679938	100.000	100.000


Table S1 Bromoaminocyclization of **1a** using thiocarbamate **6**.



entry ^a	catalyst	temperature (°C)	time (d)	yield, ^b ee (%)
1	6a	-50	3	17, 2
2	6b	-50	3	21, 0
3	6c	-50	3	15, 46
4	6d	-50	3	10, -9
5	6e	-62	3	81, 63
6	6f	-62	3	67, 68
7	6g	-50	3	63, 55
8	6h	-50	4	50, 73
9	6j	-50	5	NR
10	6k	-50	4	NR
11	6l	-50	3	NR
12	6m	-50	3	NR
13	6n	-50	3	NR

^a Reactions were carried out with **1a** (0.1 mmol), NBS (0.12 mmol), catalyst **6** (0.01 mmol) in CHCl₃ (5 mL). ^b Isolated yield.

Table S2 Optimization of the bromoaminocyclization of **1a**.



entry	halogen source	solvent	temperature (°C)	yield, ^b ee (%)
1	NBS	CHCl ₃	-60	39, 75
2	NBP	CHCl ₃	-60	78, 86
3	DBH	CHCl ₃	-60	97, 83
4	NBS	toluene	-60	trace
5	NBP	toluene	-60	trace
6	NBS	CHCl ₃ /PhMe (1:1)	-60	71, 80
7	NBS	CHCl ₃ /hexane (1:1)	-60	89, 86
8	NBP	CHCl ₃ /hexane (1:1)	-78	56, 87
9	NBP	CHCl ₃ /hexane (1:2)	-78	24, 92
10	NBP	CHCl ₃ /hexane (2:1)	-78	18, 88
11	NBP	CHCl ₃ /hexane (2:3)	-78	55, 92
12	NBP	CHCl ₃ /hexane (1:2)	-60	24, 76
13	NBP	CHCl ₃ /hexane (1:2)	-78	21, 92
14	NBP	CHCl ₃ /hexane (2:3)	-60	55, 90
16	DBH	CHCl ₃ /hexane (1:2)	-78	24, 80
17	DBH	CHCl ₃ /hexane (1:1)	-78	85, 90
18	DBH	CHCl ₃ /hexane (2:1)	-78	74, 90
19	DBH	CHCl ₃ /hexane (2:3)	-60	69, 67

^a Reactions were carried out with **1a** (0.1 mmol), halogen source (0.12 mmol), catalyst **6h** (0.01 mmol) in solvent (5 mL). ^b Isolated yield.

Table S3 Optimization of the silver salt mediated rearrangement of **2**.


entry	silver salt	substrate	R	yield, ^b ee (%)
1	AgOAc	2a	Ph	0
2	Ag ₂ CO ₃	2a	Ph	0
3	AgNO ₃	2a	Ph	83
4	Ag ₃ PO ₄	2a	Ph	0
5	Ag ₂ SO ₄	2a	Ph	0
6	AgOTf	2a	Ph	43
7	AgOTs	2a	Ph	37
8 ^c	Ag(O ₂ CCF ₃)	ent-2a , 99% ee	Ph	86, 99
9	Ag(O ₂ CCF ₃)	2b , 83% ee	4-F-C ₆ H ₄	83, 83
10	Ag(O ₂ CCF ₃)	2d , 72% ee	4-Br-C ₆ H ₄	76, 72
11	Ag(O ₂ CCF ₃)	2g , 86% ee	3-Me-C ₆ H ₄	89, 86
12	Ag(O ₂ CCF ₃)	2h , 83% ee	3-MeO-C ₆ H ₄	80, 83

^a Reactions were carried out with **2** (0.1 mmol), silver salt (0.1 mmol) in acetone/water (3:1 v/v, 5 mL) at 60 °C. ^b Isolated yield. ^c **Ent-2a** was used and the corresponding **ent-3a** was isolated as the product.

References

- (1) Zhou, L.; Tan, C. K.; Jiang, X.; Chen, F.; Yeung, Y. -Y. *J. Am. Chem. Soc.* **2010**, *132*, 15474–15476.
- (2) Zhou, L.; Chen, J.; Tan, C. K.; Yeung, Y. -Y. *J. Am. Chem. Soc.* **2011**, *133*, 9164–9167.
- (3) Tan, C. K.; Zhou, L.; Yeung, Y. -Y. *Org. Lett.* **2011**, *13*, 2738–2741.
- (4) Amat, M.; Cantó, M.; Llor, N.; Escolano, C.; Molins, E.; Espinosa, E.; Bosch, J. *J. Org. Chem.*, **2002**, *67*, 5343–5351.


¹H normal range AC300
z2291D




*** Current Data Parameters ***

NAME : oc08zl
EXPNO : 2
PROCNO : 1
*** Acquisition Parameters ***
LOCNUC : 2H
NS : 8
NUCLEUS : off
O1 : 1853.43 Hz
PULPROG : zg30
SFO1 : 300.1318534 MHz
SOLVENT : CDCl3
SW : 17.9519 ppm
TD : 32768
TE : 296.7 K
*** Processing Parameters ***
LB : 0.30 Hz
SF : 300.1300094 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off


¹³C Standard AC300
z2291d




¹H AMX500
3195-2




¹³C AMX500
3195-2



¹H AMX500
3195-1




13C AMX500
3195-1




¹H normal range AC300

3201-2




¹³C Standard AC300
3201-2




*** Current Data Parameters ***
NAME : ag27zl
EXPNO : 8
PROCNO : 1
*** Acquisition Parameters ***
BF1 : 75.4677490 MHz
LOCNUC : 2H
NS : 226
O1 : 7924.11 Hz
PULPROG : zgpg30
SFO1 : 75.4756731 MHz
SOLVENT : CDCl3
SW : 238.2968 ppm
*** Processing Parameters ***
LB : 1.00 Hz
PHC0 : 5.911 degree
PHC1 : 3.509 degree


¹H normal range AC300
3201-4




¹³C Standard AC300
3201-4




3201-5




3201-5



3201-3



3201-3



*** Current Data Parameters ***

NAME : aug26zl
EXPNO : 3
PROCNO : 1


*** Acquisition Parameters ***

BF1 : 100.6127690 MHz
LOCNUC : 2H
NS : 45
O1 : 11067.40 Hz
PULPROG : zgpg30
SFO1 : 100.6238364 MHz
SOLVENT : CDCl3
SW : 238.8943 ppm

*** Processing Parameters ***

LB : 1.00 Hz
PHC0 : 97.699 degree
PHC1 : -59.040 degree

¹H normal range AC300
3201-6



*** Current Data Parameters ***

NAME : se01zl
EXPNO : 1
PROCNO : 1

*** Acquisition Parameters ***

LOCNUC : 2H
NS : 8
NUCLEUS : off
O1 : 1853.43 Hz
PULPROG : zg30
SFO1 : 300.1318534 MHz
SOLVENT : CDCl3
SW : 17.9519 ppm
TD : 32768
TE : 296.9 K


*** Processing Parameters ***

LB : 0.30 Hz
SF : 300.1300120 MHz


*** 1D NMR Plot Parameters ***

NUCLEUS : off

13C Standard AC300
3201-6



¹H normal range AC300
2-naph



*** Current Data Parameters ***

NAME : se14zl
EXPNO : 5
PROCNO : 1

*** Acquisition Parameters ***


BF1 : 300.1300000 MHz
LOCNUC : 2H
NS : 8
O1 : 1853.43 Hz
PULPROG : zg30
SFO1 : 300.1318534 MHz
SOLVENT : Acetone
SW : 17.9519 ppm

*** Processing Parameters ***


LB : 0.30 Hz
PHC0 : 18.514 degree
PHC1 : -2.218 degree

13C Standard AC300


2-naph



1H normal range AC300
3-th




13C Standard AC300
3-th




1H normal range AC300


2-th




¹³C AMX500
2-th




trans-prod-CDCl3




trans-prod-CDCl3




¹H normal range AC300
3203-2




¹³C Standard AC300
3203-2




¹H AMX500 zl 3203-1




3203-1




4Br-P




4Br-P





¹H AMX500
3203-4




¹³C AMX500
3203-4








¹H AMX500
3203-3



¹³C AMX500
3203-3



30Me-P



*** Current Data Parameters ***

NAME : nov21zl
EXPNO : 2
PROCNO : 1


*** Acquisition Parameters ***

BF1 : 400.130000 MHz
LOCNUC : 2H
NS : 8
O1 : 2470.97 Hz
PULPROG : zg30
SFO1 : 400.1324710 MHz
SOLVENT : CDCl3
SW : 20.5524 ppm

*** Processing Parameters ***

LB : 0.30 Hz
PHC0 : -51.835 degree
PHC1 : -15.073 degree

30Me-P



*** Current Data Parameters ***

NAME : nov21zl
EXPNO : 3
PROCNO : 1


*** Acquisition Parameters ***

BF1 : 100.6127690 MHz
LOCNUC : 2H
NS : 325
O1 : 11067.40 Hz
PULPROG : zgpg30
SFO1 : 100.6238364 MHz
SOLVENT : CDCl3
SW : 238.8943 ppm


*** Processing Parameters ***

LB : 1.00 Hz
PHC0 : 91.395 degree
PHC1 : -50.951 degree


2-naph-P




2-naph-P




3203-10




3203-10




3203-9



13C AMX500
3203-9



OH-U



*** Current Data Parameters ***

NAME : nov30zl
EXPNO : 1
PROCNO : 1


*** Acquisition Parameters ***

BF1 : 400.1300000 MHz
LOCNUC : 2H
NS : 8
O1 : 2470.97 Hz
PULPROG : zg30
SFO1 : 400.1324710 MHz
SOLVENT : CDCl3
SW : 20.5524 ppm

*** Processing Parameters ***

LB : 0.30 Hz
PHC0 : -49.651 degree
PHC1 : -20.218 degree

OH-U



*** Current Data Parameters ***


NAME : nov30zl
EXPNO : 6
PROCNO : 1


*** Acquisition Parameters ***


BF1 : 100.6127690 MHz
LOCNUC : 2H
NS : 205
O1 : 11067.40 Hz
PULPROG : zgpg30
SFO1 : 100.6238364 MHz
SOLVENT : CDCl₃
SW : 238.8943 ppm


*** Processing Parameters ***


LB : 1.00 Hz
PHC0 : 96.423 degree
PHC1 : -51.530 degree























3215U




3215U



D



D



*** Current Data Parameters ***


NAME : nov02zl
EXPNO : 6
PROCNO : 1


*** Acquisition Parameters ***


BF1 : 100.6127690 MHz
LOCNUC : 2H
NS : 93
O1 : 11067.40 Hz
PULPROG : zgpg30
SFO1 : 100.6238364 MHz
SOLVENT : CDCl₃
SW : 238.8943 ppm


*** Processing Parameters ***


LB : 1.00 Hz
PHC0 : 93.411 degree
PHC1 : -45.328 degree














DT-030412-1-Ns-3-Ph-piperidine/3
13C




11




2,4-(OMe)2-isoprop




2,4-(OMe)2-isoprop



¹H normal range AC300
CPh3



13C Standard AC300
CPh3



*** Current Data Parameters ***

NAME : de24zl
EXPNO : 2
PROCNO : 1

*** Acquisition Parameters ***

LOCNUC : 2H
NS : 2599
NUCLEUS : off
O1 : 7924.11 Hz
PULPROG : zgpg30
SFO1 : 75.4756731 MHz
SOLVENT : CDCl3
SW : 238.2968 ppm
TD : 32768
TE : 679.5 K


*** Processing Parameters ***

LB : 1.00 Hz
SF : 75.4677540 MHz


*** 1D NMR Plot Parameters ***

NUCLEUS : off


2,4-(OMe)2-bigtail




2,4-(OMe)2-bigtail



171A




171A



*** Current Data Parameters ***

NAME : jul04zl
EXPNO : 9
PROCNO : 1
*** Acquisition Parameters ***
LOCNUC : 2H
NS : 1024
NUCLEUS : off
O1 : 11067.40 Hz
PULPROG : zgpg30
SFO1 : 100.6238364 MHz
SOLVENT : CDCl3
SW : 238.8943 ppm
TD : 65536
TE : 299.6 K
*** Processing Parameters ***
LB : 1.00 Hz
SF : 100.6127950 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off

¹H normal range AC300
3213D-QND



13C Standard AC300
3213D-QND-cat




Figure S1. X-ray structure of **2a**.





Figure S2. X-ray structure of **ent-3a**.

